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Expressions Related to Insulin, Lipid, and Inflammation 
Pathways in Patients With Diabetic Nephropathy
Akbar Heidari,1 Gholamali Hamidi,2 Alireza Soleimani,3 
Esmat Aghadavod,1 Zatollah Asemi1
Introduction. Data on the effects of coenzyme Q10 (CQ10) on 
gene expression related to insulin, lipid, and inflammation in 
patients with diabetic nephropathy (DN) are scarce. This study 
aimed to determine the effects of CQ10 supplementation on gene 
expression related to insulin, lipid, and inflammation pathways 
in patients with DN.
Materials and Methods. Forty patients with DN, aged 40 to 85 
years old, were randomly assigned into 2 groups to receive either 
100 mg/d of CQ10 supplements (n = 20) or placebo (n = 20), for 12 
weeks. Gene expression related to signaling pathway of insulin, 
lipid, and inflammation were determined in blood samples using 
a reverse transcriptase polymerase chain reaction method.
Results. Quantitative results of reverse transcriptase polymerase 
chain reaction demonstrated that compared with the placebo, 
CQ10 administration upregulated gene expression of peroxisome 
proliferator-activated receptor-γ (P = .02) in peripheral blood 
mononuclear cells of the patients with DN. In addition, compared 
with the placebo, CQ10 supplementation downregulated gene 
expression of interleukin-1 (P = .003) and tumor necrosis factor-α 
(P = .02). No significant effects were observed on gene expression 
of oxidized low-density lipoprotein, lipoprotein(a), glucose 
transporter-1, transforming growth factor-β in the CQ10 group.
Conclusions. Overall, CQ10 supplementation for 12 weeks in DN 
patients significantly improved gene expression of peroxisome 
proliferator-activated receptor-γ, interleukin-1, and tumor necrosis 
factor-α.
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INTRODUCTION
Previous studies have reported that various 
genetic factors involve in the pathogenesis 
of diabetic nephropathy (DN).1,2 Peroxisome 
proliferator-activated receptor-γ (PPAR-γ) is mainly 
expressed in adipose tissues,3 which controls 
adipogenesis and lipid storage. In addition, 
PPAR-γ is constitutively expressed in the kidney, 
suggesting that the kidney is a direct target tissue 
of PPAR-γ agonists.4 On the other hand, pro-
inflammatory cytokines including interleukin-1 
(IL-1) and tumor necrosis factor-α (TNF-α) have 
critical roles in pathogenesis of DN by increased 
vascular permeability, proliferation of mesangial 
cells, and impaired balance among vasodilator 
and vasoconstriction mediators.5,6
Coenzyme Q10 (CQ10) plays an important role 
in several important cellular functions, such as 
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disulfide bonds formation, scavenging reactive 
oxygen species, cell signals, and gene expression.7 
The favorable effects of CQ10 supplementation on 
metabolic profiles and inflammatory markers have 
previously been reported.8,9 In addition, beneficial 
effects of CQ10 on gene expression related to 
insulin, lipid, and inflammation have evaluated 
among subjects without DN and animal models. 
For instance, CQ10 upregulated gene expression 
of PPAR-α via the calcium-mediated adenosine 
monophosphate-activated protein kinase signal 
pathway and suppressing differentiation-induced 
adipogenesis in 3T3-L1 preadipocytes.10 Furthermore, 
Lee and coworkers11 observed that the severity of 
graft versus host disease and gene expressions of 
IL-6 and TNF-α decreased following treatment 
with CQ10. Coenzyme Q10 also increased insulin 
sensitivity and had antidiabetic properties via 
increasing the activity of phosphatidylinositol 
kinase in the liver and skeletal muscle of rats fed 
with a high-fat high-fructose diet.12
These findings might support the importance of 
CQ10 supplementation in individuals with DN. To 
our knowledge, limited data are available evaluating 
the effects of CQ10 intake on gene expression 
related to insulin, lipid, and inflammation in 
individuals with DN. The aim of this trial was to 
determine the effects of CQ10 supplementation 
on gene expression related to insulin, lipid, and 
inflammation in patients with DN.
MATERIALS AND METHODS
Study Design
This study was a randomized double-blind 
placebo-controlled clinical trial.
Participants
This trial was performed among 40 patients with 
DN aged 40 to 85 years old referred to Naghavi 
Clinic in Kashan, Iran, between December 2015 and 
March 2016. We defined DN as diabetic kidney 
disease with a proteinuria level greater than 0.3 
g/24 h, with or without circulating concentrations 
of serum creatinine.13 The exclusion criteria were 
consumption of any nutritional supplements within 
past 3 months, including vitamin E, omega-3 fatty 
acids, selenium, and CQ10; history of active infection 
within past 3 months; history of hospital admission 
within 3 months; malignancy or liver cirrhosis; 
uncontrolled diabetes mellitus; and pregnancy.
This trial was performed in accordance with 
the Declaration of Helsinki and informed consent 
forms were signed by all participants. The study 
protocol was approved by the ethics committee of 
Kashan University of Medical Sciences and was 
registered with the Iranian Registry of Clinical 
Trials (http://www.irct.ir; IRCT201611155623N93).
Methods
The participants were randomly assigned into 
2 groups to receive either 100 mg/d of CQ10 
supplement (n = 20) or placebo (n = 20) for 12 
weeks. Randomization assignment was carried 
out using computer-generated random numbers. 
Randomization and allocation were concealed 
from the researchers and participants until the 
final analyses were completed. The randomized 
allocation sequence, enrolling participants, and 
allocating them to interventions were performed 
by a trained nutritionist at the clinic.
The  CQ10  supplement  and i t s  p lacebos 
(cellulose) were manufactured by the Nature Made 
Pharmaceutical Company (New York, USA) and Barij 
Essence Pharmaceutical Company (Kashan, Iran), 
respectively. Before the intervention, participants 
were requested to keep their habitual diet and 
routine levels of physical activity throughout the 
study period. All of the participants recorded 3-day 
dietary records and 3 physical activity records at the 
study baseline and after the 12-week treatment. To 
compute daily macro- and micro-nutrient intakes 
according to the 3-day food diaries, we used the 
Nutritionist IV software (First Databank, San Bruno, 
CA) adjusted for Iranian foods.
Treatment Adherence
Every 4 weeks, the participants were given 
enough supplements to last until 3 days after 
their next scheduled visit and were instructed 
to return all the unused supplements at each 
visit. To evaluate the compliance, the remaining 
supplements were counted and subtracted from 
the amount of supplements provided. In addition, 
all of the participants received short messages on 
their cell phones every day to remind them about 
taking the capsules.
Assessment of Anthropometric Measures
Weight and height of the participants were 
determined in an overnight fasting status using a 
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standard scale (Seca, Hamburg, Germany) at baseline 
and after the 12-week intervention. Body mass index 
was calculated as weight in kg divided by height in 
squared meters. All anthropometric measurements 
were done by a trained staff at the internal clinic.
Outcomes
Gene expression of  PPAR-γ  and glucose 
transporter-1 (GLUT-1) were considered as 
the primary outcome and gene expression of 
lipoprotein(a) (Lp(a)), oxidized low-density 
lipoprotein LDL cholesterol, IL-1, IL-8, TNF-α, 
and transforming growth factor beta (TGF-β) were 
considered as the secondary outcome variables.
Isolation of Lymphocyte Cells
At baseline and after 12 weeks, 10-mL venous 
blood samples were taken after overnight fasting 
at Kashan reference laboratory. Then, lymphocyte 
cells were extracted from blood samples by the use 
of a 50% percoll gradient (Sigma-Aldrich, Dorset, 
UK). The cells of lymphocytes which were at the 
interface of percoll and serum were removed using 
a Pasteur pipette and washed a few times with 
phosphate buffer saline.14 Samples were taken 
for cell count and viability testing by trypan blue, 
RNA, and DNA extraction.14
Total RNA Extraction
For RNA extraction, the RNX-plus kit (Cinnacolon, 
Tehran, Iran) was used. After preparation of 
homogenate, the cells powder was harvested 
and resuspended in 1 mL of RNAX-plus reagent 
in a clean RNase-free tube. After incubation for 
5 minutes at room temperature, the sample was 
pipetted and subsequently treated with addition of 
200 µL of chloroform.14 The mixture was incubated 
at room temperature for 5 minutes after shaking 
rigorously for 15 seconds.14
First Strand Complementary DNA Synthesis 
Procedure
The first strand complementary DNA synthesis 
can be performed as an individual reaction or as 
a series of parallel reactions with different RNA 
templates. The isolated RNA was reverse transcribed 
to complementary DNA library using moloney 
murine leukemia virus reverse transcriptase.
Gene Expression
Expressed levels of PPAR-γ, GLUT-1, Lp(a), 
Oxidized LDL cholesterol, IL-1, IL-8, TNF-α, and 
TGF-β were evaluated by quantitative reverse 
transcriptase polymerase chain reaction, using the 
LightCycler technology (Roche Diagnostics, Rotkreuz, 
Switzerland) with a SYBR Green Detection and 
Amplicon Kit (Table). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) primers were used as 
housekeeping gene. All reactions were run in 
duplicates. To design primers, the Primer Express 
Gene Primer Product Size, bp Annealing Temperature,°C
GAPDH F: AAGCTCATTTCCTGGTATGACAACG
R: TCTTCCTCTTGTGCTCTTGCTGG
126 61.3
PPAR-γ F: ATGACAGACCTCAGACAGATTG
R: AATGTTGGCAGTGGCTCAG
210 54
GLUT-1 F: TATCTGAGCATCGTGGCCAT
R: AAGACGTAGGGACCACACAG
238 62.1
Lp(a) F: GACACAGCACGTTCATTCCA
R: ACACCCCCCTACAATGCTTC
200 55
Oxidized LDL F: ACTTACGGACAGACAGACAG
R: GGCCACACATCCCATGATTC
223 57
IL-1 F: GCTTCTCTCTGGTCCTTGG
R: AGGGCAGGGTAGAGAAGAG
174 56
IL-8 F: GCAGAGGGTTGTGGAGAAGT
R: ACCCTACAACAGACCCACAC
150 56
TNF-α F: GTCAACCTCCTCTCTGCCAT
R: CCAAAGTAGACCTGCCCAGA
188 52
TGF-β F: TTGAGACTTTTCCGTTGCCG
R: CGAGGTCTGGGGAAAAGTCT
227 56
Specific Primers Used for Real-Time Quantitative Polymerase Chain Reaction*
*GAPDH indicates glyceraldehyde-3-phosphate dehydrogenase; GLUT-1, glucose transporter-1; IL-1, interleukin-1; IL-8, interleukin-8; Lp(a), 
lipoprotein(a); LDL, low-density lipoprotein; PPAR-γ, peroxisome proliferator-activated receptor-γ; TNF-α, tumor necrosis factor-α; and TGF-β, 
transforming growth factor-β.
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Software (Applied Biosystems, Foster City) and 
Beacon Designer software (Takaposizt, Tehran, 
Iran) were used. Relative transcription levels were 
calculated by the method of Pffafi or 2-∆∆CT. Prior 
studies have shown that GAPDH is one of the 
most commonly used housekeeping genes used in 
comparisons of gene expression data.15,16 Although 
GAPDH is one of the 10 enzymes that catalyze 
reactions in the glycolytic pathway, this hypothesis 
supports that nutrition status may influence GAPDH 
expression levels.17 Nonetheless, previous studies have 
demonstrated that within-tissue variation of GAPDH 
mRNA expression levels is generally small.15,16
Statistical Methods
To evaluate whether the study variables 
were normally distributed or not, we used the 
Kolmogrov-Smirnov test. To show differences in 
anthropometric measures as well as in macro- and 
micro-nutrient dietary intakes between the two 
groups, we used independent samples t test. To 
determine the effects of CQ10 supplementation 
on gene expression related to insulin, lipid, and 
inflammation, we used independent samples t test. 
A P value less than .05 was considered significant. 
All statistical analyses used the SPSS software 
(Statistical Package for the Social Sciences, version 
18.0, SPSS Inc, Chicago, IL, USA).
RESULTS
A total of 55 patients were recruited; however, 
15 were excluded from the study because of not 
meeting inclusion criteria. Forty patients (20 in 
the placebo group and 20 in the CQ10 group) 
completed the trial (Figure 1). On average, the 
rate of adherence was high, such that higher than 
90% of the supplements were taken throughout 
the study in both groups. No side effects were 
recorded following supplementation with CQ10 
in the patients with DN throughout the study.
The mean age and height as well as baseline and 
end-of-trial weight and body mass index were not 
significantly different between the two groups, 
neither was sex distribution (data not shown). 
The two groups were not significantly different in 
terms of smoking, duration of diabetes mellitus, 
antidiabetic and antilipidemic use, hypertension, 
or angiotensin-converting enzyme inhibitors and 
aldosterone receptor blockers use. Finally, based 
on the 3-day dietary records obtained at baseline, 
end-of-trial, and throughout the trial, we found no 
signiﬁcant difference in the mean dietary macro- 
and micro-nutrient intakes between the two groups 
(data not shown).
Quantitative results of reverse transcriptase 
polymerase chain reaction demonstrated that 
compared with the placebo, CQ10 administration 
Figure 1. Summary of patient flow diagram.
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upregulated gene expression of PPAR-γ (P = .02) 
in peripheral blood mononuclear cells of the 
patients with DN, but there was no change in gene 
expression of GLUT-1 (Figure 2). Compared with the 
placebo, CQ10 supplementation did not alter gene 
expression of Oxidized LDL or LP(a) in peripheral 
blood mononuclear cells of the patients with DN 
(Figure 3), but it downregulated gene expression 
of IL-1 (P = .003) and TNF-α (P = .02). No CQ10 
influence was observed on gene expression of IL-8 
or TGF-β (Figure 4).
DISCUSSION
In this study, which to our knowledge is 
the first  of  i ts  kind, we assessed effects of 
CQ10 supplementation on gene expression of 
related to signaling pathway of insulin, lipid, 
and inflammation among those with DN. We 
demonstrated that CQ10 supplementation for 12 
weeks among patients with DN had beneficial 
effects on some gene expressions related to signaling 
pathway of insulin and inflammation. It must be 
considered that in the current study, we used 100 
mg of CQ10 supplements per day for 12 weeks, 
which was lower than usual reported dosage.18 
Although beneficial effects of the same dose of 
CQ10 were previously reported among patients 
with metabolic syndrome8 and polycystic ovary 
syndrome,19 we believe that further studies are 
needed to confirm our findings.
Diabetic nephropathy is associated with several 
metabolic complications, including insulin resistance, 
dyslipidemia, and inflammation.20 The current 
study demonstrated that taking CQ10 for 12 weeks 
in patients with DN upregulated gene expression 
of PPAR-γ, but did not alter gene expression of 
GLUT-1, Oxidized LDL, or Lp(a). However, data 
on the effects of CQ10 supplementation on gene 
expression of these proteins are scarce; few studies 
have evaluated the effects of CQ10 supplementation 
Figure 3. Effect of 12-week supplementation with coenzyme 
Q10 (CQ10) and placebo on expression ratio of Oxidized low-
density lipoprotein (LDL) and lipoprotein(a) (Lp(a)) in blood 
mononuclear cells of patients with diabetic nephropathy.
Figure 2. Effect of 12-week supplementation with coenzyme 
Q10 (CQ10) and placebo on expression ratio of peroxisome 
proliferator-activated receptor-γ (PPAR-γ) and glucose 
transporter-1 (GLUT-1) in blood mononuclear cells of patients 
with diabetic nephropathy.
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on signaling expression of insulin and lipid. Lee 
and colleagues10 observed that CQ10 resulted in 
the overexpression of PPAR-α at both the mRNA 
and protein levels in 3T3-L1 preadipocytes. In 
addition, CQ10 partially attenuated the effect of 
TNF-α on PPAR-γ, but did not change its effect 
on PPAR-α.21 Likewise, supplementation with 
CQ10 induced PPAR-α gene expression signature in 
SAMP1 mice.22 This is consistent with prior studies 
indicating that supplementation with 200 mg/d of 
CQ10 in those with type 2 diabetes mellitus for 12 
weeks,18 and 100 mg/d of CQ10 in patients with 
metabolic syndrome for 8 weeks,8 resulted in a 
significant improvement in glycemic control.
Peroxisome proliferator-activated receptor-γ is 
a nuclear receptor protein that acts as a ligand-
activated transcription factor in regulating gene 
expression and is implicated in glucose and 
insulin metabolism, differentiation, proliferation, 
survival, and inflammation.23 In addition, PPAR-γ 
plays an important function in many kidney 
diseases.24 Previous studies have shown that 
PPAR-γ activation would result in decreasing renal 
injury and the markers of glomerular dysfunction 
in the models of renal ischemia-reperfusion,25,26 
and the upregulation of PPAR-γ provides the 
protection against hypertonicity-induced cell death 
in cultured medullary interstitial cells, which 
suggests that PPAR-γ is an important survival 
factor in the kidney.27 Taking CQ10 supplements 
may induce gene expression of PPAR-γ thorough 
the calcium-mediated adenosine monophosphate-
activated protein kinase signal pathway and 
suppressing differentiation-induced adipogenesis.10
We found that CQ10 supplementation for 12 
weeks downregulated IL-1 and TNF-α expression in 
patients with DN, compared with the placebo, but 
did not affect gene expression of IL-8 and TGF-β. 
In line with our finding, in a study conducted by 
Yoneda and colleagues,28 it was seen that CQ10 
reduced gene expression of interleukin-1β, TNF-α, 
and nuclear factor-κB in rats after 8 days. Likewise, 
Lee and colleagues11 found that the severity of graft 
versus host disease and gene expressions of IL-6 and 
TNF-α decreased following treatment with CQ10. In 
another study, Premkumar and coworkers29 reported 
that CQ10 decreased the production of inflammatory 
mediators such as IL-6. In addition, our study was 
in line with another study in cardiac tissue,30 and 
CQ10 is known to have anti-inflammatory properties 
Figure 4. Effect of 12-week supplementation with coenzyme 
Q10 (CQ10) and placebo on expression ratio of interleukin 
(IL)-1, IL-8, tumor necrosis factor-α (TNF-α), and transforming 
growth factor-β (TGF-β) in blood mononuclear cells of patients 
with diabetic nephropathy.
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in mouse liver and human plasma.31,32 Previous 
studies have reported that renal mRNA expression 
of TNF-α is significantly increased approximately 
2.5-fold in DN rats compared with normal rats.33,34 
Experimental studies have indicated that urinary 
albumin excretion positively associated with renal 
cortical mRNA levels and urinary TNF-α excretion 
in animal models of DN.33,35 Furthermore, it has 
been shown that increased urinary TNF-α excretion, 
as well as increased TNF-α concentrations in renal 
interstitial fluid, result in significant increase of 
albuminuria.36 In addition, others have shown 
that IL-1 is upregulated in the diabetic kidney.33,37 
Interleukin-1 increases vascular endothelial 
permeability, and it is participated in the proliferation 
of mesangial cells and matrix synthesis, as well as 
in the progress of intraglomerular haemodynamic 
abnormalities related to prostaglandin synthesis.5 
The different findings might be explained by 
different study designs, different dosages of CQ10 
used as well as different subjects of the study. Due 
to its antioxidant and radical scavenging activity, 
CQ10 can reduce reactive oxygen species and free 
radicals, which in turn could influence TNF-α gene 
expression via the nuclear factor-κB pathway.38
This study had a few limitations. We did not 
determine CQ10 concentrations at the study baseline 
and at the end of treatment. We considered PPAR-γ 
and GLUT-1 as gene expressions related to insulin. 
However, GLUT-1 is not directly influenced by 
insulin; it was not surprising that we did not observe 
any variation of GLUT-1 gene expression following 
supplementation with CQ10. We agree that other 
insulin-dependent transporters such as GLUT-4 or 
other postreceptor steps including insulin receptor 
substrate 1 or 2 and protein kinase B are more 
important than GLUT-1. Unfortunately, due to 
funding limitations, we did not assess gene expression 
of these pathways. Therefore, measurement of these 
pathways as well as pathways related to oxidative 
stress is suggested in future studies.
CONCLUSIONS
Overall, CQ10 supplementation for 12 weeks in 
DN patients significantly improved gene expression 
of PPAR-γ, IL-1, and TNF-α, but did not affect 
GLUT-1, Oxidized LDL, LP(a), IL-8, and TGF-β.
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